The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel The PRINC (Plavix Response in Coronary Intervention) Trial

被引：50

作者：

Gladding, Patrick ^{[1
]}

Webster, Mark ^{[1
]}

Zeng, Irene ^{[1
]}

Farrell, Helen ^{[1
]}

Stewart, Jim ^{[1
]}

Ruygrok, Peter ^{[1
]}

Ormiston, John ^{[1
]}

El-Jack, Seif ^{[1
]}

Armstrong, Guy ^{[1
]}

Kay, Patrick ^{[1
]}

Scott, Douglas ^{[1
]}

Gunes, Arzu ^{[2
]}

Dahl, Marja-Liisa ^{[2
]}

机构：

[1] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1030, New Zealand

[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

来源：

JACC-CARDIOVASCULAR INTERVENTIONS | 2008年 / 1卷 / 06期

关键词：

angioplasty; catheterization pharmacology; platelets; stents;

D O I：

10.1016/j.jcin.2008.09.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives This study evaluated the antiplatelet effect of a higher loading and maintenance dose regimen of clopidogrel and a possible drug interaction with verapamil. Background Clopidogrel loading doses above 600 mg have not resulted in more rapid or complete platelet inhibition. Higher maintenance dosages may be more effective than 75 mg/day. Methods A double-blind, randomized, placebo-controlled trial was undertaken in 60 patients undergoing percutaneous coronary intervention. All patients received clopidogrel 600 mg at the start of the procedure. Using a 2 x 2 design, patients were allocated to clopidogrel 600 mg given 2 h later or matching placebo, and to verapamil 5 mg intra-arterial or placebo. Platelet function was measured using the Verify Now P2Y12 analyzer (Accumetrics Ltd., San Diego, California) at 2, 4, and 7 h. Patients were further randomized to receive a clopidogrel 75 or 150 mg once daily, with platelet function assessed after 1 week. Results Two hours after the second dose of clopidogrel or placebo, platelet inhibition was 42 +/- 27% with clopidogrel, compared with 24 +/- 22% with placebo (p = 0.0006). By 5 h after the second dose, platelet inhibition was 49 +/- 30% with clopidogrel, compared with 29 +/- 22% with placebo (p = 0.01). No drug interaction was seen with verapamil. A clopidogrel maintenance dosage of 150 mg daily for 1 week resulted in greater platelet inhibition than 75 mg daily (50 +/- 28% vs. 29 +/- 19%, p = 0.01). Conclusions In an unselected population undergoing percutaneous coronary intervention a clopidogrel 1,200-mg loading dose, given as two 600-mg doses 2 h apart, results in more rapid and complete platelet inhibition than a single 600-mg dose. A maintenance dosage of 150 mg daily produces greater platelet inhibition than 75 mg daily. (The PRINC trial; ACTRN12606000129583) (J Am Coll Cardiol Intv 2008;1:612-9) (C) 2008 by the American College of Cardiology Foundation

引用

页码：612 / 619

页数：8

共 28 条

[1] Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study [J].

Angiolillo, Dominick J. ;

Shoemaker, Steven B. ;

Desai, Bhaloo ;

Yuan, Hang ;

Charlton, Ronald K. ;

Bernardo, Esther ;

Zenni, Martin M. ;

Guzman, Luis A. ;

Bass, Theodore A. ;

Costa, Marco A. .

CIRCULATION, 2007, 115 (06) :708-716

[2] Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives [J].

Angiolillo, Dominick J. ;

Fernandez-Ortiz, Antonio ;

Bernardo, Esther ;

Alfonso, Fernando ;

Macaya, Carlos ;

Bass, Theodore A. ;

Costa, Marco A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (14) :1505-1516

[3] Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study [J].

Bonello, Laurent ;

Camoin-Jau, Laurence ;

Arques, Stephane ;

Boyer, Christian ;

Panagides, Dimitri ;

Wittenberg, Olivier ;

Simeoni, Marie-Claude ;

Barragan, Paul ;

Dignat-George, Francoise ;

Paganelli, Franck .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) :1404-1411

[4] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J].

Brandt, J. T. ;

Close, S. L. ;

Iturria, S. J. ;

Payne, C. D. ;

Farid, N. A. ;

Ernest, C. S., II ;

Lachno, D. R. ;

Salazar, D. ;

Winters, K. J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) :2429-2436

[5] A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [J].

Brandt, John T. ;

Payne, Christopher D. ;

Wiviott, Stephen D. ;

Weerakkody, Govinda ;

Farid, Nagy A. ;

Small, David S. ;

Jaknbowski, Joseph A. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN HEART JOURNAL, 2007, 153 (01) :66.e9-66.e16

[6] Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].

Gurbel, PA ;

Bliden, KP ;

Hiatt, BL ;

O'Connor, CM .

CIRCULATION, 2003, 107 (23) :2908-2913

[7] Clopidogrel resistance? [J].

Gurbel, Paul A. ;

Tantry, Udaya S. .

THROMBOSIS RESEARCH, 2007, 120 (03) :311-321

[8] The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration [J].

Jakubowski, Joseph A. ;

Payne, Christopher D. ;

Li, Ying G. ;

Brandt, John T. ;

Small, David S. ;

Farid, Nagy A. ;

Salazar, Daniel E. ;

Winters, Kenneth J. .

THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) :409-415

[9] Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization [J].

Kandzari, DE ;

Berger, PB ;

Kastrati, A ;

Steinhubl, SR ;

Mehilli, J ;

Dotzer, F ;

ten Berg, JM ;

Neumann, FJ ;

Bollwein, H ;

Dirschinger, J ;

Schömig, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2133-2136

[10] Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial [J].

Kastrati, A ;

Mehilli, J ;

Neumann, FJ ;

Dotzer, F ;

ten Berg, JN ;

Bollwein, H ;

Graf, I ;

Ibrahim, M ;

Pache, J ;

Seyfarth, M ;

Schühlen, H ;

Dirschinger, J ;

Berger, PB ;

Schömig, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1531-1538

← 1 2 3 →